[Cl:1][CH2:2][CH2:3][CH2:4][O:5][CH3:6].[Cl:7][C:8]1[C:16]([NH2:17])=[C:12]2[CH2:13][CH2:14][O:15][C:11]2=[C:10]([C:18]2[O:22][N:21]=[C:20]([CH:23]3[CH2:28][CH2:27][NH:26][CH2:25][CH2:24]3)[N:19]=2)[CH:9]=1.C(N(CC)CC)C.[I-].[K+]>CN(C)C=O>[ClH:1].[Cl:7][C:8]1[C:16]([NH2:17])=[C:12]2[CH2:13][CH2:14][O:15][C:11]2=[C:10]([C:18]2[O:22][N:21]=[C:20]([CH:23]3[CH2:28][CH2:27][N:26]([CH2:2][CH2:3][CH2:4][O:5][CH3:6])[CH2:25][CH2:24]3)[N:19]=2)[CH:9]=1A mixture of methyl (3-chloropropyl) ether (1.6 g), intermediate 4 (3.9 g), triethylamine (5 ml) and potassium iodide (a catalytic amount) in dimethylformamide (60 ml) was stirred for 48 hours at 60° C. The reaction mixture was cooled and the solvent evaporated. The residue was partitioned between CH2Cl2 and a saturated aqueous NaCl solution. The organic layer was separated, dried over MgSO4, filtered and the solvent evaporated. The residue was purified by column chromatography on silica gel (eluent: CH2Cl2 /CH3OH 90/10). The desired fractions were collected and the solvent was evaporated. The residue was solidified in DIPE, filtered off, dissolved in 2-propanol and converted into the hydrochloric acid salt (1:1) with HCl/2-propanol. The precipitate was filtered off and dried, yielding 1.14 g (22.1%) of 5-chloro-2,3-dihydro-7-[3-[1-(3-methoxypropyl)-4-piperidinyl]-1,2,4-oxadiazol-5-yl]-4-benzofuranamine monohydrochloride.hemihydrate (compound 1; mp. 244.3° C.).
Loading…